

Stress May Affect Aggressive Breast Ca Growth

BY ALICIA AULT

FROM THE AMERICAN ASSOCIATION
FOR CANCER RESEARCH

WASHINGTON – Higher levels of stress may partially account for aggressive tumor growth in African American and Hispanic women with breast cancer, according to Garth H. Rauscher, Ph.D., of the University of Illinois at Chicago.

This is one of the first studies to look closely at the potential role of psychosocial stress on tumor progression in breast cancer, said Dr. Rauscher, an associate professor of epidemiology at the university's School of Public Health. However, he acknowledged that the study is "flawed" because it is cross-sectional and has other limitations.

"This is definitely an exploratory study," Dr. Rauscher said at the meeting.

It was already known, especially in Chicago, that there was a wide disparity in mortality rates between black women and white women, said Dr. Rauscher. The data are not as well defined for Hispanic women, he said.

Tumor aggressiveness likely contributes to higher mortality rates in the minorities. Both African Americans and Hispanics generally have higher-grade tumors and hormone receptor-negative tumors, said Dr. Rauscher. The researchers wanted to investigate why these women have the more aggressive tumor types.

They chose to examine psychosocial factors.

Dr. Rauscher and his colleagues examined associations between patient-reported stress and aggressive breast cancer in a cross-sectional study of 397 non-Hispanic whites, 411 non-Hispanic blacks, and 181 Hispanics. Data were collected through patient interviews and medical record extraction. Stress was assessed using the four-item Cohen Perceived Stress Subscale, the UCLA Loneliness Scale, and the Cockburn psychological consequences scale. The three scales were combined into a single, standardized stress score.

Patients were interviewed just after their diagnosis of breast cancer. Dr. Rauscher explained that the researchers assumed that if patients were experiencing high stress post diagnosis, they were likely to have been under stress before diagnosis as well. But he acknowledged that this assumption is a major limitation of the study.

Of 989 patients, the researchers were able to get tumor grades for 772: 149 had low-grade tumors; 308 were intermediate, and 315 were high-grade tumors. A total of 21% (66 of 315) of patients with high-grade tumors reported elevated stress, 19% (58 of 308) of patients with intermediate-grade tumors reported elevated stress, and 11% (16 of 149) of patients with low-grade tumors reported elevated stress.

The differences were statistically significant, until Dr. Rauscher and his colleagues adjusted for age, treatment, income, and other factors.

A total of 28% of women with hormone receptor-negative tumors reported stress, compared with 14% of

those with receptor-positive growths. Patients with hormone receptor-negative disease reported stress one-third of a standard deviation higher than did patients with receptor-positive disease. The difference held up after adjustment, Dr. Rauscher said.

Overall, psychosocial stress scores were higher for black and Hispanic women than for whites.

There's still no way to know, however,

what accounts for those differences, said Dr. Rauscher. "If you have a more aggressive diagnosis, does that make you worry more? You could certainly put that out there as a possibility," he said. Patients with more aggressive disease might also undergo more aggressive treatment, which could also lead to greater stress, he said. "There could be causal arrows going in both directions here, but we can't tease that out." Even so, he said, "our results are

consistent with a role for stress in the etiology of aggressive breast cancer."

Dr. Rauscher suggested that other researchers could help confirm his work by delving further into existing cohort studies that measured stress and had banked tumor samples. By comparing tumor type to patients reporting stress, they might be able to tease out an association.

Dr. Rauscher reported no conflicts. ■

ADVERTISEMENT

We're committed to you and your patients

At Ther-Rx, we take our commitment to you and your patients seriously. We have heard your concerns and have taken steps to make Makena™ (hydroxyprogesterone caproate injection) more accessible for clinically eligible patients.

We believe every woman deserves access to FDA-approved and regulated medications. As the only FDA-approved medication of its kind, Makena helps fulfill important unmet needs for certain at-risk women. We understand the responsibility associated with bringing Makena to market in a reliable manner for the thousands of moms in need of therapy every year.

Our commitment to affordable patient access

With our Patient Assistance Programs, clinically eligible patients can have affordable access to therapy.* Financial assistance is available for clinically eligible insured and uninsured patients upon request.

The Makena Co-pay Assistance Program will reduce co-pay costs for insured patients whose health plan covers Makena. Patients with a household income of up to \$120,000† will pay between \$0 and \$20 per injection for Makena. Since there are no income caps, patients with a household income greater than \$120,000 are also eligible for co-pay assistance.

The Makena Patient Assistance Program supports uninsured patients by offering the drug at no cost or reduced cost. Patients who are uninsured and have an annual household income less than \$60,000 will receive Makena at no out-of-pocket cost.

Our commitment to product quality and patient safety

We believe that there is a need for a quality FDA-approved treatment.

FDA-approved Makena—a sterile injectable—is manufactured in a facility compliant with current Good Manufacturing Practices (cGMPs). These FDA-enforced regulations help ensure the identity, strength, quality, and purity of the medication by requiring control and monitoring of the manufacturing process and facilities. This also helps ensure consistency from dose to dose and accurate potency according to the amount declared on the label.¹ Adherence to these quality-management systems means your patients will receive the FDA-approved formulation for this indication.²

Makena is the only product for this indication that has been studied in clinical trials conducted by the NICHD and subsequently reviewed and approved by the FDA. As an FDA-approved medication, Makena is also subject to ongoing safety monitoring for adverse effects.

Our commitment to ongoing support

In addition to access to FDA-approved Makena, your patients will have access to educational materials and compliance reminders throughout therapy.

We established the Makena Care Connection™ to help facilitate the prescription process via a standardized distribution system. As part of this effort, dedicated specialists are available to support you, your staff, and your patients throughout the prescription process.

Our commitment goes beyond simply bringing Makena to market. We are conducting large follow-up trials on Makena, designed in collaboration with the FDA. These studies will help provide enhanced medical knowledge to patients, families, and society as a whole.

*Each patient's eligibility is evaluated on an individual basis. Program eligibility criteria are subject to change. Financial assistance programs are administered by the Makena Cares Foundation, which is managed by the Chronic Disease Fund.

†This encompasses 85% of US household incomes. Source: 2009 US census data.

References: 1. Facts About Current Good Manufacturing Practices (cGMPs). Available at: <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturing/ucm169105.htm>. Accessed July 22, 2011. 2. CFR - Code of Federal Regulations Title 21. Available at: <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=211&showFR=1&subpartNode=21.4.0.1.1.11.6>. Accessed July 22, 2011.

Visit www.makena.com for additional information about Makena.

Please see next page for important safety information.

Which Came First – Stress or Disease?

University of Illinois at Chicago researchers who investigated a possible connection between stress and aggressive breast cancer tumor types offered a healthy reality check along with their results. They point out that their study's results may be flawed by the classic "chicken or egg" dilemma inherent in measuring stress levels following a diagnosis.

Did higher rates of stress instigate or

propel tumor growth long term, setting the stage for aggressive disease in these women, or was their elevated stress a normal response to learning that they had an aggressive form of breast cancer, requiring more intensive treatment and a less optimistic prognosis?

The promise in this study is its approach, focusing on the possibility that psychosocial stress plays a role in the development of aggressive breast



118:1181), glucose intolerance (Psychoneuroendocrinology 2008;33:517-29. Epub 2008 Mar 11), and cardio-

cancer. It is certainly plausible, and fits with accumulating evidence that stress hormones are associated with prematurity and low birth weight (Int. J. Neurosci 2008;

vascular disease (J. Am. Coll. Cardiol. 2008;51:1237-46).

Longitudinal studies, ideally obtaining stress data in healthy subjects prior to diagnoses of cancer and other diseases, could offer illuminating insight in the contribution of psychosocial factors to disease development.

BETSY BATES FREED, Psy.D., is a clinical psychologist in Santa Barbara, Calif, and a medical journalist. She has no relevant financial disclosures.

ADVERTISEMENT

Makena™ is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. The effectiveness of Makena is based on improvement in the proportion of women who delivered <37 weeks of gestation. There are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity.

Limitation of use: While there are many risk factors for preterm birth, safety and efficacy of Makena has been demonstrated only in women with a prior spontaneous singleton preterm birth. It is not intended for use in women with multiple gestations or other risk factors for preterm birth.

Important safety information for Makena

- Makena should not be used in women with any of the following conditions:
 - Current or history of thrombosis or thromboembolic disorders
 - Known or suspected breast cancer, other hormone-sensitive cancer or history of these conditions
 - Undiagnosed abnormal vaginal bleeding unrelated to pregnancy
 - Cholestatic jaundice of pregnancy
 - Liver tumors, benign or malignant, or active liver disease
 - Uncontrolled hypertension
- Makena should be discontinued if thrombosis or thromboembolism occurs
- Allergic reactions, including urticaria, pruritus and angioedema, have been reported with use of Makena or with other products containing castor oil
- Women receiving Makena should be monitored if they:
 - Are prediabetic or diabetic
 - Have conditions that may be affected by fluid retention, such as preeclampsia, epilepsy, cardiac or renal dysfunction
 - Have a history of clinical depression; Makena should be discontinued if depression recurs
 - Develop jaundice; consider whether benefit of use warrants continuation
 - Develop hypertension
- Certain pregnancy-related fetal and maternal complications or events were numerically increased in Makena-treated subjects as compared to placebo subjects, including miscarriage (2.4% vs. 0%) and stillbirth (2% vs. 1.3%), admission for preterm labor (16% vs. 13.8%), preeclampsia or gestational hypertension (8.8% vs. 4.6%), gestational diabetes (5.6% vs. 4.6%), and oligohydramnios (3.6% vs. 1.3%)
- The most common adverse reactions reported in ≥2% of subjects and at a higher rate in the Makena group than in the control group were injection site reactions (pain [35% vs. 33%], swelling [17% vs. 8%], pruritus [6% vs. 3%], and nodule [5% vs. 2%]), urticaria (12% vs. 11%), pruritus (8% vs. 6%), nausea (6% vs. 5%), and diarrhea (2% vs. 1%)

FDA-Approved
Makena[™]
 hydroxyprogesterone
 caproate injection

Every week counts[™]

Please see next page for brief summary
 of prescribing information.

Ther-Rx
 CORPORATION

Marketed by Ther-Rx Corporation, St. Louis, MO 63044
 © 2011 Ther-Rx Corporation 17-154-1 8/11